Literature DB >> 20069756

Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent.

Séverine Fagète1, Ulla Ravn, Franck Gueneau, Giovanni Magistrelli, Marie H Kosco-Vilbois, Nicolas Fischer.   

Abstract

Chemokines are important mediators of the immune response that are responsible for the trafficking of immune cells between lymphoid organs and migration towards sites of inflammation.Using phage display selection and a functional screening approach, we have isolated a panel of single-chain fragment variable (scFv) capable of neutralizing the activity of the human chemokine CXCL10 (hCXCL10). One of the isolated scFv was weakly cross-reactive against another human chemokine CXCL9,but was unable to block its biological activity. We diversified the complementarity determining region 3 (CDR3) of the light chain variable domain (VL) of this scFv and combined phage display with high throughput antibody array screening to identify variants capable of neutralizing both chemokines. Using this approach it is therefore possible to engineer pan-specific antibodies that could prove very useful to antagonize redundant signaling pathways such as the chemokine signaling network.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20069756      PMCID: PMC2726596          DOI: 10.4161/mabs.1.3.8527

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  26 in total

Review 1.  Structure, function, and inhibition of chemokines.

Authors:  Elias J Fernandez; Elias Lolis
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

2.  Antibody arrays for high-throughput screening of antibody-antigen interactions.

Authors:  R M de Wildt; C R Mundy; B D Gorick; I M Tomlinson
Journal:  Nat Biotechnol       Date:  2000-09       Impact factor: 54.908

3.  Antibody multispecificity mediated by conformational diversity.

Authors:  Leo C James; Pietro Roversi; Dan S Tawfik
Journal:  Science       Date:  2003-02-28       Impact factor: 47.728

Review 4.  Manufacture of recombinant polyclonal antibodies.

Authors:  S K Rasmussen; L K Rasmussen; D Weilguny; A B Tolstrup
Journal:  Biotechnol Lett       Date:  2007-02-20       Impact factor: 2.461

Review 5.  The many roles of chemokines and chemokine receptors in inflammation.

Authors:  Israel F Charo; Richard M Ransohoff
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

Review 6.  Antibody engineering for therapeutics.

Authors:  Leonard Presta
Journal:  Curr Opin Struct Biol       Date:  2003-08       Impact factor: 6.809

7.  Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.

Authors:  R Schier; A McCall; G P Adams; K W Marshall; H Merritt; M Yim; R S Crawford; L M Weiner; C Marks; J D Marks
Journal:  J Mol Biol       Date:  1996-11-08       Impact factor: 5.469

8.  In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity.

Authors:  C F Barbas; D Hu; N Dunlop; L Sawyer; D Cababa; R M Hendry; P L Nara; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

Review 9.  Chemokine: receptor structure, interactions, and antagonism.

Authors:  Samantha J Allen; Susan E Crown; Tracy M Handel
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

10.  IFN-gamma-inducible chemokines enhance adaptive immunity and colitis.

Authors:  Udai P Singh; Shailesh Singh; Nuzhat Iqbal; Casey T Weaver; Jerry R McGhee; James W Lillard
Journal:  J Interferon Cytokine Res       Date:  2003-10       Impact factor: 2.607

View more
  9 in total

Review 1.  Engineering the variable region of therapeutic IgG antibodies.

Authors:  Tomoyuki Igawa; Hiroyuki Tsunoda; Taichi Kuramochi; Zenjiro Sampei; Shinya Ishii; Kunihiro Hattori
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

2.  Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry.

Authors:  Séverine Fagète; François Rousseau; Giovanni Magistrelli; Franck Gueneau; Ulla Ravn; Marie H Kosco-Vilbois; Nicolas Fischer
Journal:  J Biol Chem       Date:  2011-10-31       Impact factor: 5.157

3.  Tuning the specificity of a Two-in-One Fab against three angiogenic antigens by fully utilizing the information of deep mutational scanning.

Authors:  Patrick Koenig; Sarah Sanowar; Chingwei V Lee; Germaine Fuh
Journal:  MAbs       Date:  2017-06-06       Impact factor: 5.857

4.  Guidelines, Strategies, and Principles for the Directed Evolution of Cross-Reactive Antibodies Using Yeast Surface Display Technology.

Authors:  Sara Linciano; Ee Lin Wong; Ylenia Mazzocato; Monica Chinellato; Tiziano Scaravetti; Alberto Caregnato; Veronica Cacco; Zhanna Romanyuk; Alessandro Angelini
Journal:  Methods Mol Biol       Date:  2022

5.  Improvements to the Kunkel mutagenesis protocol for constructing primary and secondary phage-display libraries.

Authors:  Renhua Huang; Pete Fang; Brian K Kay
Journal:  Methods       Date:  2012-08-30       Impact factor: 3.608

6.  Beyond natural antibodies: the power of in vitro display technologies.

Authors:  Andrew R M Bradbury; Sachdev Sidhu; Stefan Dübel; John McCafferty
Journal:  Nat Biotechnol       Date:  2011-03       Impact factor: 54.908

7.  A novel highly potent therapeutic antibody neutralizes multiple human chemokines and mimics viral immune modulation.

Authors:  Michelle L Scalley-Kim; Bruce W Hess; Ryan L Kelly; Anne-Rachel F Krostag; Kurt H Lustig; John S Marken; Pamela J Ovendale; Aaron R Posey; Pamela J Smolak; Janelle D L Taylor; C L Wood; David L Bienvenue; Peter Probst; Ruth A Salmon; Daniel S Allison; Teresa M Foy; Carol J Raport
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

Review 8.  Small molecule inhibitors of CXCR4.

Authors:  Bikash Debnath; Shili Xu; Fedora Grande; Antonio Garofalo; Nouri Neamati
Journal:  Theranostics       Date:  2013-01-15       Impact factor: 11.556

9.  Directed Evolution of a Highly Specific FN3 Monobody to the SH3 Domain of Human Lyn Tyrosine Kinase.

Authors:  Renhua Huang; Pete Fang; Zengping Hao; Brian K Kay
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.